image_top

WE INNOVATE SUSTAINABLY

Vers C. Elegans
04/07/2021

With the comeback of free-range farming, parasitism is a big topic. BIOARMOR research program was presented at technical day on this topic in October 2020 at ISPAIA (Superior Institute of Animal Productions and Agrofood Industries).


BIOARMOR has been conducting the Nutrilogic project for several years. Our goal is to find natural alternatives to conventional medication.

The project particularly deals with essential oils and their activity towards specific issues: antibacterial, anti-inflammatory, antioxidant…

The feature of this project is also his experimental design with the nematode Caenorhabditis elegans. « this one-millimetre-long transparent round worm has been used as study model of cell development for a long time in medicine, pharmacy, cosmetics,… but still little known in animal productions. Our know-how should lead to new cooperations and innovations», explained Marie LANG, PhD of R&D BIOARMOR team, during her presentation.

At BIOARMOR, we use it for an additional dual use: it allows us to study the host-pathogen relationship, that means the relationship between the animal and a pathogen such as a bacterium (here salmonella enterica), but also to test the antiparasitic activity of several blends of essential oils.  The polyvalence of the worm makes it not only interesting from scientific point of view, but also it allows to set up a predictive model in an ethical way, without using vertebrate animals. ». This gives many opportunities as experimentation on animals is more and more restricted.

Thanks to lab results of this project, a product aimed at supporting ruminant digestive health is being tested together with ISPAIA to validate the predictive nature of this scientific model: « Field trials have to prove now the validity of the model on one set of bacteria, but also its deworming effect », Marie Lang specifies. Anne LE ROUX from ISPAIA adds “Trials thus allow to validate a virtuous approach, to which our institute brings a scientific backing, thanks to its status and trials protocols. »